Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: A randomized trial

Annals of Internal Medicine

Volumn 166, Issue 2, 2017, Pages 109-117

  Colombo, Massimo ^a   Aghemo, Alessio ^a   Liu, Hong ^b   Zhang, Jie ^b   Dvory Sobol, Hadas ^b   Hyland, Robert ^b   Yun, Chohee ^b   Massetto, Benedetta ^b   Brainard, Diana M ^b   McHutchison, John G ^b   Bourlière, Marc ^c   Peck Radosavljevic, Markus ^d   Manns, Michael ^e   Pol, Stanislas ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b GILEAD SCIENCES   (United States)

^c HÔPITAL SAINT JOSEPH   (France)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f Hopital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN; LEDIPASVIR PLUS SOFOSBUVIR; TRIACYLGLYCEROL LIPASE; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LEDIPASVIR; SOFOSBUVIR;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIVIRAL THERAPY; ARTERIOVENOUS SHUNT; ARTICLE; ASTHENIA; BLOODY DIARRHEA; CHRONIC HEPATITIS C; COMPENSATED LIVER CIRRHOSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYSIPELAS; ESTIMATED GLOMERULAR FILTRATION RATE; FAINTNESS; FATIGUE; FEMALE; GASTROENTERITIS; GLUCOSURIA; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPONATREMIA; INCISIONAL HERNIA; INTERNATIONAL NORMALIZED RATIO; INTERVERTEBRAL DISK HERNIA; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHUNT THROMBOSIS; SIDE EFFECT; SUICIDE ATTEMPT; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTOPENIA; THYROID PAPILLARY CARCINOMA; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URINARY TRACT INFECTION; ANTIVIRAL RESISTANCE; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; GENOTYPE; GLOMERULUS FILTRATION RATE; HEPATITIS C, CHRONIC; MIDDLE AGED;

ADULT; AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; GENOTYPE; GLOMERULAR FILTRATION RATE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SOFOSBUVIR;

EID: 85016986156     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-1205     Document Type: Article

References (33)

1. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: metaanalysis of observational studies. Am J Transplant. 2005;5:1452-61. [PMID: 15888054]
2. Kamar N, Alric L, Izopet J, Rostaing L. Hepatitis C virus and kidney disease. Clin Res Hepatol Gastroenterol. 2013;37:328-33. [PMID: 23522570] doi:10.1016/j.clinre.2013.02.010
3. Corouge M, Vallet-Pichard A, Pol S. HCV and the kidney. Liver Int. 2016;36 Suppl 1:28-33. [PMID: 26725894] doi:10.1111/liv.13022
4. Su FH, Su CT, Chang SN, Chen PC, Sung FC, Lin CC, et al. Association of hepatitis C virus infection with risk of ESRD: a populationbased study. Am J Kidney Dis. 2012;60:553-60. [PMID: 22554802] doi:10.1053/j.ajkd.2012.04.003
5. Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, et al; R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012; 206:469-77. [PMID: 22811301] doi:10.1093/infdis/jis385
6. Molnar MZ, Alhourani HM, Wall BM, Lu JL, Streja E, Kalantar- Zadeh K, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatology. 2015;61:1495-502. [PMID: 25529816] doi:10.1002/hep.27664
7. Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z. A metaanalytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. J Viral Hepat. 2015;22:897-905. [PMID: 25904153] doi:10.1111/jvh.12413
8. Scott DR, Wong JK, Spicer TS, Dent H, Mensah FK, McDonald S, et al. Adverse impact of hepatitis C virus infection on renal replace ment therapy and renal transplant patients in Australia and New Zealand. Transplantation. 2010;90:1165-71. [PMID: 20861806] doi:10.1097/TP.0b013e3181f92548
9. Mahmoud IM, Elhabashi AF, Elsawy E, El-Husseini AA, Sheha GE, Sobh MA. The impact of hepatitis C virus viremia on renal graft and patient survival: a 9-year prospective study. Am J Kidney Dis. 2004; 43:131-9. [PMID: 14712436]
10. Carpio R, Pamugas GE, Danguilan R, Que E. Outcomes of renal allograft recipients with hepatitis C. Transplant Proc. 2016;48:836-9. [PMID: 27234747] doi:10.1016/j.transproceed.2016.02.050
11. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008:S1-99. [PMID: 18382440] doi:10.1038/ki.2008.81
12. Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015;12:284-92. [PMID: 25895822] doi:10.1038/nrgastro.2015.53
13. Beinhardt S, Al Zoairy R, Ferenci P, Kozbial K, Freissmuth C, Stern R, et al. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transpl Int. 2016;29:999-1007. [PMID: 27203857] doi:10.1111/tri.12799.
14. Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016;16:1588-95 [PMID: 26604182] doi:10.1111/ajt.13620
15. Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssière L, et al. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant. 2016;16:1474-9. [PMID: 26587971] doi:10.1111/ajt .13518
16. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-93. [PMID: 24725238] doi:10.1056/NEJMoa1316366
17. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-98. [PMID: 24725239] doi:10.1056/NEJMoa1402454
18. Abergel A, Metivier S, Samuel D, Jiang D, Kersey K, Pang PS, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology. 2016;64:1049-56. [PMID: 27351341] doi:10.1002/hep.28706
19. Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16:459-64. [PMID: 26803446] doi:10.1016/S1473-3099(15)00529-0
20. Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149:1454-1461. [PMID: 26261007] doi:10.1053/j .gastro.2015.07.063
21. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932-54. [PMID: 26111063] doi:10.1002/hep.27950
22. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199-236. [PMID: 25911336] doi:10.1016/j.jhep.2015.03.025
23. German P, Pang PS, Fang L, Chung D, Mathias A. Drug-drug interaction profile of the fixed-dose combination tablet ledipasvir/sofosbuvir. Hepatology. 2014;60 (Suppl):1162A.
24. German P, Mathias A, Brainard D, Kearney BP. Clinical pharmacokinetics and pharmacodynamics of ledipasvir/sofosbuvir, a fixeddose combination tablet for the treatment of hepatitis C. Clin Pharmacokinet. 2016. [PMID: 27193156]
25. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26:404-13.
26. Suraweera D, Sundaram V, Saab S. Treatment of hepatitis C virus infection in liver transplant recipients. Gastroenterol Hepatol (NY). 2016;12:23-30. [PMID: 27330501]
27. Felmlee DJ, Coilly A, Chung RT, Samuel D, Baumert TF. New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis. 2016;16:735-45. [PMID: 27301929] doi:10.1016/S1473-3099(16)00120-1
28. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, et al; SOLAR-1 Investigators. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-59. [PMID: 25985734] doi:10.1053/j.gastro.2015.05.010
29. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al; SOLAR-2 Investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685-97. [PMID: 26907736] doi:10.1016/S1473-3099(16)00052-9
30. Kwo PY, Badshah MB. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease. Curr Opin Organ Transplant. 2015;20: 235-41. [PMID: 25944238] doi:10.1097/MOT.0000000000000198
31. Fontaine H, Lazarus A, Pol S, Pecriaux C, Bagate F, Sultanik P, et al; Cochin Hepatology and Cardiology Group. Bradyarrhythmias associated with sofosbuvir treatment [Letter]. N Engl J Med. 2015; 373:1886-8. [PMID: 26535533] doi:10.1056/NEJMc1505967#SA1
32. Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, et al; HCV-TARGET. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807-16. [PMID: 26923436] doi:10.1111/liv.13102
33. Reese PP, Abt PL, Blumberg EA, Goldberg DS. Transplanting hepatitis C-positive kidneys. N Engl J Med. 2015;373:303-5. [PMID: 26200976] doi:10.1056/NEJMp1505074